Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia

Wander, P.; Cheung, Laurence; Pinhanҫos, S.S.; Jones, L.; Kerstjens, M.; Arentsen-Peters, S.T.C.J.M.; Singh, S.; Chua, G.A.; Castro, P.G.; Schneider, P.; Dolman, M.E.M.; Koopmans, B.; Molenaar, J.J.; Pieters, R.; Zwaan, C.M.; Kotecha, Rishi; Stam, R.W.

doi:10.1038/s41375-020-0895-9

Access Status

Fulltext not available

Authors

Wander, P.

Cheung, Laurence

Pinhanҫos, S.S.

Jones, L.

Kerstjens, M.

Arentsen-Peters, S.T.C.J.M.

Singh, S.

Chua, G.A.

Castro, P.G.

Schneider, P.

Dolman, M.E.M.

Koopmans, B.

Molenaar, J.J.

Pieters, R.

Zwaan, C.M.

Kotecha, Rishi

Stam, R.W.

Date

2020

Type

Journal Article

Metadata

Show full item record

Citation

Wander, P. and Cheung, L.C. and Pinhanҫos, S.S. and Jones, L. and Kerstjens, M. and Arentsen-Peters, S.T.C.J.M. and Singh, S. et al. 2020. Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia. Leukemia.

Source Title

Leukemia

DOI

10.1038/s41375-020-0895-9

ISSN

0887-6924

Faculty

Faculty of Health Sciences

School

School of Pharmacy and Biomedical Sciences

URI

http://hdl.handle.net/20.500.11937/79575

Collection

Curtin Research Publications

Abstract

The treatment of children diagnosed with acute lymphoblastic leukemia (ALL) has improved significantly over recent decades, with 5-year event-free survival (EFS) approaching 85% [1]. However, 5-year EFS for infants diagnosed at less than 1 year of age with MLL-rearranged ALL remains less than 40% [2]. MLL-rearranged infant ALL is both clinically and biologically distinct from other childhood ALL subtypes, which is reflected by a unique gene expression profile [3], a remarkably silent mutational landscape [4], and pronounced resistance to currently applied chemotherapeutics [5].